Is SpyGlass Pharma, Inc. Common Stock (SGP) a Buy, Sell, or Hold?
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
$20.6 USD
$0.61 (3.05%)
- Volume
- 146.38K
- Average Volume
- 98.95K
- Market Capitalization
- $688.73M
- P/E Ratio
- -19.25
- Dividend Yield
- 0.00%
- Price Target
- $62.00
- Year High
- $32.44
- Year Low
- $17.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $38.00
| Source | Headline |
|---|---|
|
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth. globenewswire.com - 2026-06-15 08:00:00 |
|
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president, marketing. globenewswire.com - 2026-06-02 08:00:00 |
|
SpyGlass Pharma to Participate in Upcoming Investor Conferences
ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026Time: 2:00 p.m. globenewswire.com - 2026-05-21 08:00:00 |
|
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
ALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new add-on Category III CPT code for attachment and insertion of intraocular lens prosthesis-mounted drug-eluting implant, based on the application submitted for the Bimatoprost Drug Pad-IOL System (BIM-IOL System), in conjunction with established Category I cataract surgery procedure codes. globenewswire.com - 2026-05-18 08:00:00 |
|
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the first quarter ended March 31, 2026. globenewswire.com - 2026-05-14 16:05:00 |
